Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Opioid Induced Constipation Clear all
Completed Phase 2 Interventional Results available

Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures

NCT00640146
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Methylnaltrexone bromide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 17, 2026, 4:09 AM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.

NCT00399659
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Timeline
2006 – 2007
U.S. locations
57
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional

A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)

NCT01401985
View directory record Official record
Conditions
Opioid Induced Constipation
Interventions
TD-1211, Placebo
Drug
Lead sponsor
Glycyx Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Terminated Phase 4 Interventional Results available

Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)

NCT02839889
View directory record Official record
Conditions
Cancer, Constipation, Pain
Interventions
Naloxegol, Placebo
Drug
Lead sponsor
Hospice of Henderson County, Inc.
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
New York, New York • Flat Rock, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone

NCT00595946
View directory record Official record
Conditions
Opioid-Induced Bowel Dysfunction
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
94
States / cities
Birmingham, Alabama • Hueytown, Alabama • Mobile, Alabama + 79 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

A Study of Naldemedine (S-297995) for the Treatment of Opioid-Induced Constipation in Adults With Non-Malignant Chronic Pain Receiving Opioid Therapy

NCT01443403
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Placebo, Naldemedine
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
49
States / cities
Phoenix, Arizona • Sun Lakes, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Sep 17, 2026, 4:09 AM EDT
Not listed Phase 3 Interventional

Naloxone in Treating Constipation in Patients Who Are Receiving Opioids for Chronic Pain

NCT00020605
View directory record Official record
Conditions
Constipation, Impaction, and Bowel Obstruction, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
naloxone hydrochloride
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Sep 17, 2026, 4:09 AM EDT
Withdrawn Phase 4 Interventional

Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects

NCT00858754
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
methylnaltrexone, placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
4
States / cities
Laguna Hills, California • Lancaster, California • Flat Rock, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

NCT01309841
View directory record Official record
Conditions
Opioid-Induced Constipation (OIC)
Interventions
NKTR-118, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 84 Years
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
91
States / cities
Birmingham, Alabama • Calera, Alabama • Glendale, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated May 31, 2015 · Synced Sep 17, 2026, 4:09 AM EDT
Completed No phase listed Observational

Longitudinal Study of Patients With Opioid-Induced Constipation

NCT01928953
View directory record Official record
Conditions
Patients With Opioid Induced Constipation
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 85 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
24
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Sep 17, 2026, 4:09 AM EDT
Withdrawn No phase listed Observational

RELISTOR's Effects on Opioid-Induced Constipation

NCT04930237
View directory record Official record
Conditions
OIC
Interventions
Relistor Injectable Product, Docusate Calcium, Bisacodyl, Milk of magnesia, Magnesium citrate, Senna, Enema
Drug
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Terminated Phase 3 Interventional Results available

Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain

NCT01384292
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
NKTR-118, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
81
States / cities
Huntsville, Alabama • Casa Grande, Arizona • Phoenix, Arizona + 78 more
Source: ClinicalTrials.gov public record
Updated May 31, 2015 · Synced Sep 17, 2026, 4:09 AM EDT
Not listed No phase listed Observational

Naloxegol US PMR CV Safety.

NCT02813356
View directory record Official record
Conditions
Opioid Induced Constipation
Interventions
naloxegol, non-PAMORA
Drug
Lead sponsor
Valinor Pharma LLC
Industry
Eligibility
Not listed
Enrollment
8,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Wilmington, Delaware • Hines, Illinois
Source: ClinicalTrials.gov public record
Updated May 14, 2023 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation

NCT01993940
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Naldemedine, Placebo
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 80 Years
Enrollment
553 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
49
States / cities
Birmingham, Alabama • Homewood, Alabama • Goodyear, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Opioid-induced Bowel Dysfunction: Long-Term Assessment of Lubiprostone

NCT00620061
View directory record Official record
Conditions
Opioid-Induced Bowel Dysfunction
Interventions
Lubiprostone 24
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years and older
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
120
States / cities
Birmingham, Alabama • Hueytown, Alabama • Mobile, Alabama + 95 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2020 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Not applicable Interventional Results available

Compassionate Use Study of Methylnaltrexone

NCT01368562
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Methylnaltrexone
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 4 Interventional Results available

Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness

NCT00672477
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
Methylnaltrexone, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
29
States / cities
Mobile, Alabama • Laguna Hills, California • Lancaster, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation

NCT01333540
View directory record Official record
Conditions
Opioid-induced Constipation (OIC)
Interventions
TD-1211, Placebo
Drug
Lead sponsor
Glycyx Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional

Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain

NCT00366431
View directory record Official record
Conditions
Constipation
Interventions
MOA-728
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
67
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation

NCT00804141
View directory record Official record
Conditions
Constipation
Interventions
N-methylnaltrexone bromide (MOA-728)
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
94
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain

NCT01186770
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
Methylnaltrexone, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain

NCT02270983
View directory record Official record
Conditions
Opioid-Induced Constipation
Interventions
Linaclotide 145 micrograms, Linaclotide 290 micrograms, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
77
States / cities
Anniston, Alabama • Foley, Alabama • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2019 · Synced Sep 17, 2026, 4:09 AM EDT
Terminated Phase 2Phase 3 Interventional

Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain

NCT00365820
View directory record Official record
Conditions
Constipation
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
670 participants
Timeline
2006 – 2007
U.S. locations
59
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Sep 17, 2026, 4:09 AM EDT
Completed Phase 4 Interventional Results available

To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation

NCT03060512
View directory record Official record
Conditions
Opioid Induced Constipation
Interventions
Polyethylene Glycol 3350, Movantik
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 84 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
53
States / cities
Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2018 · Synced Sep 17, 2026, 4:09 AM EDT